Page results
-
Information about the integrated occupational therapy service at the Royal London Hospital for Integrated Medicine
-
Information about the integrated general medicine service at the Royal London Hospital for Integrated Medicine.
-
The Integrated Children’s and Adolescent Service has been established to provide complementary care alongside orthodox treatments. The clinic sees children up to 18 years old with a wide variety of illnesses.
-
Our education department at the Royal London Hospital for Integrated Medicine, runs courses in integrated medicine for statutory registered health professionals.
-
The Royal London Hospital for Integrated Medicine (RLHIM) is a centre for evidence-based practice, education and research, specialising in chronic and complex medical conditions.
-
The primary objective of the ENT urgent referral clinic is to provide speedy access and effective care to all adult and paediatric patients aged above two years old with urgent ENT problems.
-
RESPOND is a new rapid access, community-based screening and care planning system for all asylum-seeking families registered with a GP in North Central London.
-
Please see below for information relating to various vaccination services offered at UCLH. To check which vaccinations you’ve had in the past, view your GP record using your NHS account or…
-
This page answers common questions about cryotherapy.
File results
-
FOI/2023/0007 - Outpatient activity for 2022
-
FOI/2023/0009 - Procedure volumes/ average costs for portable and stable oxygen concentrator devices
-
FOI/2023/0010 - Bardet-biedle Syndrome patient treatment and diagnosis
-
FOI/2023/0013 - Average waiting times for colonoscopy investigations
-
FOI/2023/0014 - Surgery protocols/ standard operating procedures for a feticide
-
FOI/2023/0018 - A&E attendances/ admissions by patients of no fixed abode
-
FOI/2023/0019 - Public access to water refill stations on your premises
-
FOI/2023/0022 - Guidelines staff follow for patients with disabilities and autism
-
FOI/2023/0226 - Treatment with Nivolumab
-
FOI/2023/0225 - Usage of Dabrafenib + Trametinib in cancer treatment